Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA8 | P11142 | 3/20 | 0.57 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.57 |
| ▸ | AMD1 | P17707 | 5/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | GAPDH | P04406 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | SLC28A2 | O43868 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | HBB | P68871 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | PNP | P00491 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14075808 | 1.00 | HSPA8 (0.57) | HSPA8HSPA5AMD1RXFP1GAPDH | |
| SCHEMBL27626941 | 0.88 | NADK (0.54) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| SCHEMBL28638932 | 0.88 | LMNA (0.61) | HSPA8HSPA5AMD1RXFP1GAPDH | |
| SCHEMBL6439152 | 0.88 | HSPA8 (0.52) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| SCHEMBL14075810 | 0.88 | HSPA8 (0.55) | HSPA8HSPA5AMD1RXFP1GAPDH | |
| SCHEMBL5034807 | 0.88 | HSPA8 (0.55) | HSPA8HSPA5AMD1RXFP1GAPDH | |
| SCHEMBL6439878 | 0.88 | NADK (0.54) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| SCHEMBL5034818 | 0.88 | HSPA8 (0.55) | HSPA8HSPA5AMD1RXFP1GAPDH | |
| SCHEMBL15906323 | 0.84 | HSPA8 (0.80) | HSPA8HSPA5AMD1RXFP1GAPDH | |
| SCHEMBL13787725 | 0.84 | HSPA8 (0.56) | HSPA8HSPA5AMD1RXFP1GAPDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4379052-A2 | MRNA PURIFICATION BY TANGENTIAL FLOW FILTRATION | Ethris GmbH (DE) | 2024-06-05 | — | — | EP | claimed |
| CN-113396219-B | Purification of mRNA by tangential flow filtration | ETHRIS GMBH (DE) | 2026-05-26 | — | — | CN | disclosed |
| US-12622960-B2 | Varicella zoster virus (VZV) vaccine | MODERNATX, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-12612658-B2 | RNA replication using transcription polymerases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-04-28 | — | — | US | disclosed |
| EP-3458081-B1 | POLYNUCLEOTIDES ENCODING CITRIN FOR THE TREATMENT OF CITRULLINEMIA TYPE 2 | MODERNATX INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12582609-B2 | Cancer vaccines | MODERNATX, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260071215-A1 | SYSTEMS FOR ENHANCING TARGET MRNA EXPRESSION AND USES THEREOF | UNIV JOHNS HOPKINS (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260071212-A1 | GalNAc conjugated oligonucleotides for RNA editing | KORRO BIO INC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-3752610-B1 | POLYRIBONUCLEOTIDE CONTAINING DEUTERATED NUCLEOTIDES | ETHRIS GMBH (DE) | 2026-01-28 | — | — | EP | disclosed |
| US-12522821-B2 | Polyribonucleotide containing deuterated nucleotides | ETHRIS GMBH (DE) | 2026-01-13 | — | — | US | disclosed |
| WO-2017070618-A1 | CANCER VACCINES | MODERNATX, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017070622-A1 | RESPIRATORY SYNCYTIAL VIRUS VACCINE | MODERNATX, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017070601-A1 | NUCLEIC ACID VACCINES FOR VARICELLA ZOSTER VIRUS (VZV) | MODERNATX, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017070623-A1 | HERPES SIMPLEX VIRUS VACCINE | MODERNATX, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017066789-A1 | MRNA CAP ANALOGS WITH MODIFIED SUGAR | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066782-A1 | HYDROPHOBIC MRNA CAP ANALOGS | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066781-A1 | MRNA CAP ANALOGS WITH MODIFIED PHOSPHATE LINKAGE | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066793-A1 | MRNA CAP ANALOGS AND METHODS OF MRNA CAPPING | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066791-A1 | SUGAR SUBSTITUTED MRNA CAP ANALOGS | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066797-A1 | TRINUCLEOTIDE MRNA CAP ANALOGS | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582609-B2 | Cancer vaccines | RNMT, MICA, NSUN2 | HSPA8 1409/4885HSPA5 2256/4885AMD1 2944/4885 |
| US-20260071215-A1 | SYSTEMS FOR ENHANCING TARGET MRNA EXPRESSION AND USES THEREOF | UPF1, RBM26, RPRD2 | HSPA8 1392/4885HSPA5 727/4885AMD1 2118/4885 |
| US-12622960-B2 | Varicella zoster virus (VZV) vaccine | NSUN2, RNMT, RNGTT | HSPA8 1831/4885HSPA5 4180/4885AMD1 2964/4885 |
| US-12612658-B2 | RNA replication using transcription polymerases | RNGTT, POLRMT, POLM | HSPA8 2281/4885HSPA5 1969/4885AMD1 1050/4885 |
| US-20260071212-A1 | GalNAc conjugated oligonucleotides for RNA editing | NSUN3, ADAR, TRMT1L | HSPA8 4851/4885HSPA5 4450/4885AMD1 2164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.